Hon Andrew LittleMinister of Health
The addition of another drug to the suite of COVID-19 medicines available in New Zealand is good news for patients and
for the health system, the Government says.
“Preventing people from getting COVID-19 in the first place, through vaccinations, social distancing and mask-wearing,
is still the best protection for people and for keeping the health system free for those who need it,” Health Minister
Andrew Little said.
“But we need medicines for those who do get sick, which is why I am very pleased that the national
pharmaceuticals-buying agency Pharmac has secured supplies of another drug shown to work against the COVID-19 virus.
“Baricitinib is the fifth drug Pharmac has secured, and sits alongside remdesivir, tocilizumab, molnupiravir and
Ronapreve as treatments doctors can turn to for people with a range of COVID-19 symptoms.
“Like tocilizumab, baricitinib can be used to treat patients who are very sick, as it reduces the severity of symptoms
and cuts time in hospital and reduces the likelihood of death.
“Pharmac expects to receive 500 doses of baricitinib this month, which is important because there is a global shortage
of tocilizumab and this gives clinicians another option,” Andrew Little said.
Money for all five medicines will come from the Government’s COVID-19 fund. Baricitinib has yet to be approved by
Medsafe for use against COVID-19, but clinicians will be able to use it straight away under Section 25 of the Medicines
Act.